# Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN.

> **NCT03413176** · — · COMPLETED · sponsor: **Groupe Hospitalier Pitie-Salpetriere** · enrollment: 150000 (actual)

## Conditions studied

- Cardiac Complication
- Vascular Diseases

## Interventions

- **DRUG:** Cardiac complication induced by VEGF/VEGFR inhibitor

## Key facts

- **NCT ID:** NCT03413176
- **Lead sponsor:** Groupe Hospitalier Pitie-Salpetriere
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2018-01-15
- **Final completion:** 2018-01-31
- **Target enrollment:** 150000 (ACTUAL)
- **Last updated:** 2019-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03413176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03413176, "Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03413176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*